Group 1 - The State Intellectual Property Office of China has granted a patent for a method of preparing L96 side-chain compounds to Suzhou Fushilai Pharmaceutical Co., Ltd. and Suzhou Kuntai Biotechnology Co., Ltd., with the patent announcement number CN118993970B and application date of May 2023 [1] - Suzhou Fushilai Pharmaceutical Co., Ltd. was established in 2000, located in Suzhou, and primarily engages in the manufacturing of chemical raw materials and products, with a registered capital of 91.67 million RMB [1] - Suzhou Fushilai has invested in 4 companies, participated in 57 bidding projects, holds 20 trademark registrations, 108 patents, and possesses 82 administrative licenses [1] - Suzhou Kuntai Biotechnology Co., Ltd. was founded in 2022, also located in Suzhou, focusing on research and experimental development, with a registered capital of 50 million RMB [1] - Suzhou Kuntai has participated in 6 bidding projects, holds 4 patents, and has 4 administrative licenses [1]

Core Viewpoint - The company is actively preparing for the NDA submission of Fluorine-18 labeled Somatostatin Injection, with an expected submission in the first half of 2026, although the approval timeline remains uncertain [1] Group 1 - The company is currently working on the NDA submission preparations for the Fluorine-18 Somatostatin Injection [1] - The expected timeline for NDA submission is the first half of 2026 [1] - The approval timeline is uncertain and will depend on regulatory requirements [1]

Group 1 - The company has a cultivation license for cannabis in the United States but is not currently engaged in related operations [1] - The U.S. project company is not included in the company's consolidated financial statements [1] - Ongoing litigation regarding a stock buyback dispute is affecting the company's involvement in the U.S. project [1]

Market Overview - The Shanghai Composite Index rose by 0.69% to 3917 points on December 22, with significant gains in the Hainan sector driven by the duty-free concept, while the SPD concept declined, leading to notable losses in the millet economy and banking sectors [1]. High-Performing Stocks - Victory Energy achieved a seven-day consecutive rise, with a price increase of 49.98% to 28.75, attributed to control changes and developments in robotics [3][4]. - Jia Mei Packaging recorded a 10.05% increase, reaching 6.68, benefiting from control changes and its position as a leader in three-piece cans [4]. - Zhuangyuan Pasture and Luyuan Pharmaceutical both saw a 10.04% increase, with prices at 15.02 and 20.09% respectively, driven by the dairy and pet economy [4]. - Changfei Fiber and Shenjian Co. also performed well, with increases of 10% and 10.04% respectively, supported by advancements in optical fiber technology and commercial aerospace [4]. Trading Activity - The top three net buying stocks on the Dragon and Tiger list were Shanzi Gaokao, Haima Automobile, and Shennong Seed Industry, with net purchases of 688 million, 302 million, and 260 million respectively [5][6]. - Conversely, the top three net selling stocks included Wangzi New Materials, Xue Ren Group, and Central Mall, with net sales of 192 million, 111 million, and 88 million respectively [7]. Company Highlights - Snowman Group reported a total revenue of 1.631 billion yuan, a year-on-year increase of 24.26%, and a net profit of 39.17 million yuan, up 16.63%, indicating steady growth in both revenue and profit [19]. - The company is recognized as a leading manufacturer of ice-making systems and is actively expanding into the fuel cell industry, showcasing its diversified technological advantages [19]. - The company has also established a partnership for drug promotion and raw material supply, highlighting its advantages in the industry chain [12]. Stock Performance - Haima Automobile reached a daily limit increase with a turnover rate of 17.18% and a transaction volume of 2.577 billion yuan, with a net purchase of 302 million from the Dragon and Tiger list [20]. - Shenjian Co. also hit the daily limit, with a turnover rate of 31.53% and a transaction volume of 2.225 billion yuan, despite a net sell-off of 40.25 million by institutions [20].

证券日报网讯12月22日，泓博医药（301230）在互动平台回答投资者提问时表示，股价走势受宏观环 境、行业周期及市场情绪等多重因素影响，涨跌属于市场行为。公司目前经营稳定，业务发展持续向 好，公司管理层对公司的未来发展充满信心，并将持续聚焦主营业务，不断提升公司经营质量和盈利能 力，致力于为投资者创造长期、可持续的价值回报。未来如有相关计划，公司将及时履行信息披露义 务。 ...

毕得医药公告称，2025年11月13日至12月19日，股东舟山兰旦企业管理合伙企业（有限合伙）及其一致 行动人吴波、舟山欣曦企业管理合伙企业（有限合伙）合计减持公司股份102.24万股，占总股本 1.12%。本次权益变动后，三者合计持股比例由11.12%降至10%，触及5%整数倍。本次减持系履行此前 计划，不触及要约收购，不会对公司治理及经营产生重大影响，减持计划尚未实施完毕。 ...

浙江医药：股东计划于1月16日至4月15日期间减持不超过公司2%的股份。 ...

Core Viewpoint - Warner Pharmaceuticals (688799) has received approval from the National Medical Products Administration for the registration certificate of Isoproterenol Hydrochloride Injection, which is used for treating cardiogenic or infectious shock, complete atrioventricular block, and cardiac arrest [1] Group 1 - The approval of Isoproterenol Hydrochloride Injection marks a significant milestone for the company in expanding its product offerings in critical care [1] - The drug is indicated for serious medical conditions, potentially increasing its market demand and relevance in emergency medicine [1] - This development may enhance the company's competitive position within the pharmaceutical industry, particularly in the cardiovascular treatment segment [1]

证券之星消息，12月22日化学制药板块较上一交易日上涨0.28%，康芝药业领涨。当日上证指数报收于 3917.36，上涨0.69%。深证成指报收于13332.73，上涨1.47%。化学制药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日化学制药板块主力资金净流入4250.38万元，游资资金净流出1.77亿元，散户资 金净流入1.34亿元。化学制药板块个股资金流向见下表： ...

Core Viewpoint - The company expresses strong confidence in its future development prospects and emphasizes its commitment to maximizing shareholder value through various means to promote sustainable development [1] Group 1 - The company focuses on its core business operations [1] - The company aims to maximize value for all shareholders [1] - The company is committed to sustainable development [1]